Bavarian Nordic (English Wikipedia)

"Archive.ph". Archived from the original on 2022-03-13. Retrieved 2023-09-08.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
"Sponsors / Donors". Bipartisan Commission on Biodefense. Archived from the original on 2022-05-29. Retrieved 2022-06-20.

bavarian-nordic.com

"Hellerup, Denmark". Bavarian Nordic. Archived from the original on March 13, 2022. Retrieved 6 December 2021.
"Board of Directors". BN. Retrieved 2024-04-08.
"Executive Management". BN. Archived from the original on 2020-07-17. Retrieved 2024-04-08.
"Annual Report 2023" (PDF). Bavarian Nordic. Archived from the original (PDF) on April 2, 2024. Retrieved April 8, 2024.
"Pipeline". Bavarian Nordic. 2020-02-20. Retrieved 2020-07-14.
"Annual Report 2019, Pipeline (p.30)" (PDF). Bavarian Nordic. Retrieved 2020-07-15.
"Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents". Bavarian Nordic. 2023-08-06. Retrieved 2024-05-02.
"Chikungunya". Bavarian Nordic. Retrieved 2024-05-02.
"Bavarian Nordic Announces Topline Results from Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine". Bavarian Nordic. 2020-06-08. Retrieved 2020-07-15.
"Equine Encephalitis". Bavarian Nordic. Retrieved 2024-05-02.

id.bavarian-nordic.com

"Infectious Diseases: Filovirus Vaccine". Bavarian Nordic. Archived from the original on 2014-10-30. Retrieved 2014-10-29.
"Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN® Ebola Vaccine". Bavarian Nordic. 2014-10-22. Archived from the original on 2014-11-03. Retrieved 2014-10-29.

biodefensecommission.org

"Sponsors / Donors". Bipartisan Commission on Biodefense. Archived from the original on 2022-05-29. Retrieved 2022-06-20.

bipartisanpolicy.org

"2017 Annual Report" (PDF). Bipartisan Policy Center. 2017. Archived (PDF) from the original on 2022-07-07. Retrieved 2022-07-07.

doi.org

Kennedy JS, Greenberg RN (9 January 2014). "IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine". Expert Review of Vaccines. 8 (1): 13–24. doi:10.1586/14760584.8.1.13. PMC 9709931. PMID 19093767. S2CID 35854977.
Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P (2016). "A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN) in 56-80-Year-Old Subjects". PLOS ONE. 11 (6): e0157335. Bibcode:2016PLoSO..1157335G. doi:10.1371/journal.pone.0157335. PMC 4915701. PMID 27327616.

europa.eu

ema.europa.eu

"Imvanex". Human Medicines. European Medicines Agency. 27 May 2016. Archived from the original on 2018-06-20. Retrieved 2016-06-12.

fda.gov

"Jynneos". U.S. Food and Drug Administration (FDA). 24 September 2019. STN 125678. Archived from the original on 17 October 2019. Retrieved 16 October 2019. This article incorporates text from this source, which is in the public domain.

fiercepharma.com

"Bavarian Nordic scoops up Emergent's travel vaccines, manufacturing site in deal worth up to $380M". Fierce Pharma. Retrieved 20 February 2023.

gcs-web.com

johnsonandjohnson.gcs-web.com

"Johnson & Johnson Announces European Commission Approval for Janssen's Preventive Ebola Vaccine". Reuters. Reuters. 2020-07-01. Retrieved 2020-07-16.

gsk.com

"GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic | GSK". www.gsk.com. Retrieved 2020-04-03.

harvard.edu

ui.adsabs.harvard.edu

Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P (2016). "A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN) in 56-80-Year-Old Subjects". PLOS ONE. 11 (6): e0157335. Bibcode:2016PLoSO..1157335G. doi:10.1371/journal.pone.0157335. PMC 4915701. PMID 27327616.

hc-sc.gc.ca

"Products for Human Use. Submission #144762". Register of Innovative Drugs. Health Canada. 13 June 2014. 144762 (Submission Number). Archived from the original on 17 June 2014. Retrieved 2014-06-26.

healthpolicy-watch.news

Exclusive: Closure of World’s Only Manufacturing Plant for Monkeypox Vaccine Raises Questions About World’s Ability to Meet Rising Demand

medicalcountermeasures.org

"Member Organizations". Medical Countermeasures Coalition. Retrieved 2 May 2024.

nasdaqomx.com

indexes.nasdaqomx.com

"OMX Copenhagen 25 (OMXC25CAP)" (PDF). Nasdaq OMX. Archived from the original (PDF) on 13 March 2022.

nih.gov

ncbi.nlm.nih.gov

Kennedy JS, Greenberg RN (9 January 2014). "IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine". Expert Review of Vaccines. 8 (1): 13–24. doi:10.1586/14760584.8.1.13. PMC 9709931. PMID 19093767. S2CID 35854977.
Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P (2016). "A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN) in 56-80-Year-Old Subjects". PLOS ONE. 11 (6): e0157335. Bibcode:2016PLoSO..1157335G. doi:10.1371/journal.pone.0157335. PMC 4915701. PMID 27327616.

pubmed.ncbi.nlm.nih.gov

Kennedy JS, Greenberg RN (9 January 2014). "IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine". Expert Review of Vaccines. 8 (1): 13–24. doi:10.1586/14760584.8.1.13. PMC 9709931. PMID 19093767. S2CID 35854977.
Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P (2016). "A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN) in 56-80-Year-Old Subjects". PLOS ONE. 11 (6): e0157335. Bibcode:2016PLoSO..1157335G. doi:10.1371/journal.pone.0157335. PMC 4915701. PMID 27327616.

niaid.nih.gov

"Smallpox Vaccine Supply & Strength". National Institute of Allergy and Infectious Diseases (NIAID). 26 September 2019. Archived from the original on 17 October 2019. Retrieved 16 October 2019.

pharmatimes.com

Smith, Anna (2019-10-21). "GSK to divest Rabipur, Encepur to Bavarian Nordic". PharmaTimes. Retrieved 2020-04-03.

reuters.com

"BRIEF-Bavarian Nordic to expand collaboration with Janssen". reuters-brief. Reuters. 2014-10-23. Archived from the original on 2014-10-30. Retrieved 2014-10-29.
"J&J, Bavarian Nordic start clinical tests in Ebola vaccine race". Reuters. Reuters. 2015-01-06. Archived from the original on 2015-01-13. Retrieved 2015-01-12.

semanticscholar.org

api.semanticscholar.org

Kennedy JS, Greenberg RN (9 January 2014). "IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine". Expert Review of Vaccines. 8 (1): 13–24. doi:10.1586/14760584.8.1.13. PMC 9709931. PMID 19093767. S2CID 35854977.

web.archive.org

"OMX Copenhagen 25 (OMXC25CAP)" (PDF). Nasdaq OMX. Archived from the original (PDF) on 13 March 2022.
"Hellerup, Denmark". Bavarian Nordic. Archived from the original on March 13, 2022. Retrieved 6 December 2021.
"Executive Management". BN. Archived from the original on 2020-07-17. Retrieved 2024-04-08.
"Annual Report 2023" (PDF). Bavarian Nordic. Archived from the original (PDF) on April 2, 2024. Retrieved April 8, 2024.
"Products for Human Use. Submission #144762". Register of Innovative Drugs. Health Canada. 13 June 2014. 144762 (Submission Number). Archived from the original on 17 June 2014. Retrieved 2014-06-26.
"Imvanex". Human Medicines. European Medicines Agency. 27 May 2016. Archived from the original on 2018-06-20. Retrieved 2016-06-12.
"Jynneos". U.S. Food and Drug Administration (FDA). 24 September 2019. STN 125678. Archived from the original on 17 October 2019. Retrieved 16 October 2019. This article incorporates text from this source, which is in the public domain.
"Smallpox Vaccine Supply & Strength". National Institute of Allergy and Infectious Diseases (NIAID). 26 September 2019. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
"Infectious Diseases: Filovirus Vaccine". Bavarian Nordic. Archived from the original on 2014-10-30. Retrieved 2014-10-29.
"Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN® Ebola Vaccine". Bavarian Nordic. 2014-10-22. Archived from the original on 2014-11-03. Retrieved 2014-10-29.
"BRIEF-Bavarian Nordic to expand collaboration with Janssen". reuters-brief. Reuters. 2014-10-23. Archived from the original on 2014-10-30. Retrieved 2014-10-29.
"Johnson & Johnson plans Ebola vaccine testing". AP.org. AP News. 2014-10-22. Archived from the original on 2014-10-31. Retrieved 2014-10-29.
"J&J, Bavarian Nordic start clinical tests in Ebola vaccine race". Reuters. Reuters. 2015-01-06. Archived from the original on 2015-01-13. Retrieved 2015-01-12.
"2017 Annual Report" (PDF). Bipartisan Policy Center. 2017. Archived (PDF) from the original on 2022-07-07. Retrieved 2022-07-07.